PolyPid Ltd. announced the appointment of Nurit Tweezer-Zaks, M.D., M.B.A, to its Board of Directors, effective November 6, 2023, following the retirement of Anat Tsour Segal. Dr. Tweezer-Zaks is a biopharmaceutical industry veteran with extensive executive business development, clinical, and R&D expertise. She is an experienced sector investor and was a practicing physician for nearly 15 years.

Dr. Tweezer-Zaks currently serves as Chief Executive Officer of MediCane Health, a fully-integrated global medical cannabis company. Previously, Dr. Tweezer-Zaks served in increasingly senior positions at aMOON, a leading Israel-based life sciences-focused venture capital investor. In her most recent role as Chief Medical Officer at aMOON, she managed the internal and external interfaces across the fund between investors, portfolio companies, and investment teams, and provided professional input to the investment committee.

Prior to this, Dr. Tweezer-Zaks held increasingly senior positions at Sanofi. In her most recent role at Sanofi, she served as Global Established Products Medical Lead ? Strategic Decision for Portfolio Enhancement.

In this role Dr. Tweezer-Zaks focused on life cycle management of portfolio products. She began her career as a practicing internal medicine physician at Sheba Medical Center in Israel. Dr. Tweezer-Zaks has authored numerous scientific publications.

She holds M.D. and B.S. degrees from Ben-Gurion University School of Medicine in Beer Sheva, Israel, and earned an M.B.A. from the Kellogg-Recanati International Executive MBA Program, a global partnership program between Northwestern University?s Kellogg School of Management in Evanston, IL, and Tel Aviv University?s Recanati Graduate School of Business Administration in Israel.